金币
UID379758
帖子
主题
积分7762
注册时间2018-8-14
最后登录1970-1-1
听众
性别保密
|
发表于 2020-5-9 08:41:09
|
显示全部楼层
【Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial | The Lancet】Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population. Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1·23 [95% CI 0·87–1·75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1·52 [0·95–2·43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early.
这是中国临床试验的论文摘要。 |
|